Can nanomedicine improve the effectiveness of drugs used to treat neglected tropical diseases?

References

• 1. WHO. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. (2020). www.who.int/publications/i/item/9789240010352
  Google Scholar
• 2. WHO. Neglected tropical diseases. www.who.int/health-topics/neglected-tropical-diseases
  Google Scholar
• 3. Ferreira LL, de Moraes J, Andricopulo AD. Approaches to advance drug discovery for neglected tropical diseases. Drug Discov. Today 27(8), 2278–2287 (2022).
  Medline CASGoogle Scholar
• 4. de Moraes J, Geary TG. FDA-approved antiparasitic drugs in the 21st century: a success for helminthiasis? Trends Parasitol. 36(7), 573–575 (2022).
  Google Scholar
• 5. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323(9), 844–853 (2020).
  MedlineGoogle Scholar
• 6. Mengarda AC, Iles B, Longo JPF, de Moraes J. Recent trends in praziquantel nanoformulations for helminthiasis treatment. Expert. Opin. Drug Deliv. 19(4), 383–393 (2022).
  Medline CASGoogle Scholar
• 7. Mengarda AC, Iles B, Longo JPF, de Moraes J. Recent approaches in nanocarrier-based therapies for neglected tropical diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. e1852 doi:10.1002/wnan.1852 (2022) (Epub ahead of print).
  MedlineGoogle Scholar
• 8. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191–200 (2012).
  Medline CASGoogle Scholar
• 9. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol. Divers. 25(3), 1315–1360 (2021).
  Medline CASGoogle Scholar
• 10. Wu Q, Ke H, Li D, Wang Q, Fang J, Zhou J. Recent progress in machine learning-based prediction of peptide activity for drug discovery. Curr. Top. Med. Chem. 19(1), 4–16 (2019).
  Medline CASGoogle Scholar
• 11. Figueiró Longo JP, Muehlmann LA. How has nanomedical innovation contributed to the COVID-19 vaccine development? Nanomedicine 16(14), 1179–1181 (2021).
  Google Scholar
• 12. Longo JPF, Mussi S, Azevedo RB, Muehlmann LA. Issues affecting nanomedicines on the way from the bench to the market. J. Mater. Chem. B 8(47), 10681–10685 (2020).
  Medline CASGoogle Scholar
• 13. de Lima LI, Py-Daniel KR, Guimarães MA et al. Self-nanoemulsifying drug-delivery systems improve oral absorption and antischistosomal activity of epiisopiloturine. Nanomedicine 13(7), 689–702 (2018).
  Google Scholar
• 14. Galdino de Souza D, Santos DS, Simon KS et al. Fish oil nanoemulsion supplementation attenuates bleomycin-induced pulmonary fibrosis BALB/c mice. Nanomaterials (Basel) 12(10), 1683 (2022).
  MedlineGoogle Scholar
• 15. Santos DS, Morais JAV, Vanderlei ÍAC et al. Oral delivery of fish oil in oil-in-water nanoemulsion: development, colloidal stability and modulatory effect on in vivo inflammatory induction in mice. Biomed. Pharmacother. 133, 110980 (2021).
  Medline CASGoogle Scholar
• 16. El-Moslemany RM, Eissa MM, Ramadan AA, El-Khordagui LK, El-Azzouni MZ. Miltefosine lipid nanocapsules: intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. Acta Trop. 159, 142–148 (2016).
  Medline CASGoogle Scholar
• 17. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43(7), 917–924 (2006).
  Medline CASGoogle Scholar